Cigna’s Two New Value-Based Contracts with Pharma for PCSK9 Inhibitor Cholesterol Drugs Tie Financial Terms to Improved Cus...
May 11 2016 - 8:30AM
Business Wire
Cigna (NYSE: CI) has entered into new value-based contracts with
both Amgen and Sanofi/Regeneron for their PCSK9 inhibitors for
commercial business. The contracts modify the cost of the new
cholesterol-lowering drugs Repatha TM and Praluent®
based on how well customers respond to the medications, aligning
incentives by linking financial terms to improved customer
health.
Praluent and Repatha were approved last year by the U.S. Food
and Drug Administration as the first two specialty drugs in a new
class known as PCSK9 inhibitors. They are intended for certain
individuals at high risk for cardiovascular diseases who aren’t
able to adequately control their “bad cholesterol” (LDL-C) levels
through other treatments, such as dietary changes and their highest
tolerated dose of a statin.
Cigna is the first health service company to reach value-based
agreements for its commercial business with both Sanofi/Regeneron
and Amgen for their PCSK9 inhibitor drugs. The contracts are
independent of each other, but they share the same overall
objective. If Cigna's customers aren’t able to reduce their LDL-C
levels at least as well as what was experienced in clinical trials,
the two pharmaceutical companies will further discount the cost of
the drugs. If the drugs meet or exceed expected LDL-C reduction,
the original negotiated price remains in place.
“Pharmaceutical advances hold great promise for improving the
health of Cigna’s customers, and outcomes-based agreements help
ensure that this promise is delivered,” said Christopher Bradbury,
senior vice president, integrated clinical and specialty drug
solutions for Cigna Pharmacy Management. “Innovating through the
contracting approach is one way we are helping our customers and
clients receive more value for their health care dollar.”
Also, by analyzing integrated medical and pharmacy claim data,
Cigna will be able to determine whether there are cardiovascular
improvements for Cigna customers related to their treatment with
the new medications beyond reduction in their cholesterol
levels.
Including the agreements with Sanofi/Regeneron and Amgen, Cigna
now has value-based contracts in place with pharmaceutical
companies covering medications for cholesterol, heart failure,
diabetes, multiple sclerosis, and hepatitis C.
Customer engagement is also a critical factor impacting health
and financial outcomes. Cigna, one of the nation’s largest pharmacy
benefit managers and specialty pharmacies, provides customers with
extensive clinical and health coaching support across their
pharmacy, medical, behavioral and disability benefits.
Cardiovascular disease is a major driver of total health care
costs. According to the Centers for Disease Control and Prevention,
nearly one-third of adults in the United States has high
cholesterol and is at elevated risk for developing heart disease.
Fewer than one in three individuals with high cholesterol has the
condition under control.
About Cigna
Cigna Corporation (NYSE: CI) is a global health service company
dedicated to helping people improve their health, well-being and
sense of security. All products and services are provided
exclusively by or through operating subsidiaries of Cigna
Corporation, including Connecticut General Life Insurance Company,
Cigna Health and Life Insurance Company, Life Insurance Company of
North America and Cigna Life Insurance Company of New York. Such
products and services include an integrated suite of health
services, such as medical, dental, behavioral health, pharmacy,
vision, supplemental benefits, and other related products including
group life, accident and disability insurance. Cigna maintains
sales capability in 30 countries and jurisdictions, and has more
than 90 million customer relationships throughout the world. To
learn more about Cigna®, including links to follow us on Facebook
or Twitter, visit www.cigna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160511005755/en/
Cigna CorporationMedia Contact:Karen Eldred,
860-787-7015karen.eldred@cigna.com
Cigna (NYSE:CI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Apr 2023 to Apr 2024